Advances in metformin‐delivery systems for diabetes and obesity management

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: 26(9), P. 3513 - 3529

Published: July 10, 2024

Abstract Metformin is a medication that commonly prescribed to manage type 2 diabetes. It has been used for more than 60 years and highly effective in lowering blood glucose levels. Recent studies indicate metformin may have additional medical benefits beyond treating diabetes, revealing its potential therapeutic uses. Oral administer because of convenience cost‐effectiveness. However, there are challenges optimizing effectiveness. Gastrointestinal side effects limitations bioavailability led the underutilization metformin. Innovative drug‐delivery systems such as fast‐dissolving tablets, micro/nanoparticle formulations, hydrogel microneedles explored optimize therapy. These strategies enhance dosage, targeting, stability, provide personalized treatment options improved homeostasis, antiobesity metabolic health benefits. Developing new delivery shows improving outcomes, broadening applications diabetes management addressing unmet needs various clinical settings. it important improve systems, issues complexity, cost, biocompatibility, stability during storage transportation, loading capacity, required technologies biomaterials, targeting precision regulatory approval. Addressing these crucial effective, safe accessible drug practice. In this review, recent advances development application metformin‐delivery obesity discussed.

Language: Английский

---

BARIATRIC SURGERY SIGNIFICANTLY REDUCES PROGRESSION FROM PREDIABETES TO DIABETES COMPARED TO GENERAL POPULATION: A 15-YEAR SINGLE INSTITUTION DATA

Surgery for Obesity and Related Diseases, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

---

Metformin as a disease-modifying therapy in osteoarthritis: bridging metabolism and joint health

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: March 19, 2025

Background Osteoarthritis (OA) and impaired glucose tolerance (IGT) frequently coexist, leading to compounded clinical metabolic challenges. This study investigates the effects of metformin in improving both outcomes (pain, stiffness, physical function) parameters (inflammatory markers, lipid profile, BMI) patients with knee OA IGT. Methods The included 60 diagnosed Participants were divided into two groups: 26 received standard treatment without (Without Metf), while 34 (500 mg twice daily) for 3 months, addition (With Metf). Clinical assessments (WOMAC, Lequesne Algofunctional Index, KOOS, VAS) markers (CRP, NLR, SOD, measured before treatment, after 1 month, months. Results With Metf group showed significantly greater improvements pain, function, quality life compared Without group. Metformin also led significant reductions inflammatory profiles health indicators. demonstrated enhanced BMI, waist-to-hip ratio, waist-to-height ratio. Furthermore, need increased NSAID doses was predicted by factors such as pain severity markers. Conclusion effectively alleviates osteoarthritis symptoms improves Further research is needed explore its long-term on joint health, potential role management

Language: Английский

---

Investigating the Effects of Gossypetin on Cardiovascular Function in Diet-Induced Pre-Diabetic Male Sprague Dawley Rats

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(22), P. 12105 - 12105

Published: Nov. 11, 2024

Gossypetin (GTIN) is a naturally occurring flavonoid recognised for its pharmacological properties. This study examined the effects of GTIN on cardiovascular function in diet-induced pre-diabetic rat model, which has not been previously studied. Pre-diabetes was induced using high-fat high-carbohydrate (HFHC) diet supplemented with 15% fructose water 20 weeks. Thereafter, animals were sub-divided into five groups (

Language: Английский

---

Interleukin-35: A key player managing pre-diabetes and chronic inflammatory type 1 autoimmune diabetes

World Journal of Diabetes, Journal Year: 2024, Volume and Issue: 15(10), P. 2147 - 2151

Published: Sept. 26, 2024

Interleukin-35 (IL-35) is a novel protein comprising IL-12α and IL-27β chains. The IL12A EBI3 genes are responsible for its production. study of IL-35 has experienced substantial increase in interest recent years, as demonstrated by many research papers. Recent clinical studies have shown that individuals who do not C-peptide notably reduced amounts their blood serum. This accompanied drop the percentage IL-35+ Treg cells, regulatory B CD8+ FOXP3+ cells produce IL-35. article em-phasizes potential significance expression governing immune response involvement chronic inflammatory autoimmune diabetes pancreatic inflammation. It demonstrates IL-35's ability to regulate cytokine proportions, modulate protect against diabetes. However, further investigation necessary ascertain precise mechanism IL-35, meticulous planning essential studies.

Language: Английский

---

From "Medication shortcut" to "Dependence": A qualitative study of self-management paradox in Chinese patients with type 2 diabetes

Patient Education and Counseling, Journal Year: 2024, Volume and Issue: 130, P. 108491 - 108491

Published: Nov. 9, 2024

Language: Английский

---